Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Emanuele D’Amico, Cinzia Caserta & Francesco Patti. (2015) Monoclonal antibody therapy in multiple sclerosis: critical appraisal and new perspectives. Expert Review of Neurotherapeutics 15:3, pages 251-268.
Read now
Read now
François Curtin, Hervé Perron, Arno Kromminga, Hervé Porchet & Alois B Lang. (2015) Preclinical and early clinical development of GNbAC1, a humanized IgG4 monoclonal antibody targeting endogenous retroviral MSRV-Env protein. mAbs 7:1, pages 265-275.
Read now
Read now
François Curtin & Hans-Peter Hartung. (2014) Novel therapeutic options for multiple sclerosis. Expert Review of Clinical Pharmacology 7:1, pages 91-104.
Read now
Read now
Alessandra Lugaresi, Maria di Ioia, Daniela Travaglini, Erika Pietrolongo, Eugenio Pucci & Marco Onofrj. (2013) Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis. Neuropsychiatric Disease and Treatment 9, pages 893-914.
Read now
Read now
Maria Chiara G Monaco & Eugene O Major. (2012) The link between VLA-4 and JC virus reactivation. Expert Review of Clinical Immunology 8:1, pages 63-72.
Read now
Read now
Masaaki Niino. (2011) Therapeutic application of monoclonal antibodies in multiple sclerosis: focus on alemtuzumab. Degenerative Neurological and Neuromuscular Disease 1, pages 33-42.
Read now
Read now
Florence Uettwiller, Emilie Rigal & Cyrille Hoarau. (2011) Infections associated with monoclonal antibody and fusion protein therapy in humans. mAbs 3:5, pages 461-466.
Read now
Read now
Articles from other publishers (19)
Zeinab Jan, Samaneh Mollazadeh, Khalil Abnous, Seyed Mohammad Taghdisi, Abolghasem Danesh, Mohammad Ramezani & Mona Alibolandi. (2022) Targeted Delivery Platforms for the Treatment of Multiple Sclerosis. Molecular Pharmaceutics 19:7, pages 1952-1976.
Crossref
Crossref
Wenhuan Wang, Xiaochun Tan, Jie Jiang, Yiqi Cai, Fangfang Feng, Lifang Zhang & Wenshu Li. (2021) Targeted Biological Effect of An Affitoxin Composed of an HPV16E7 Affibody Fused with Granzyme B (ZHPV16E7-GrB) Against Cervical Cancer In vitro and In vivo. Current Cancer Drug Targets 21:3, pages 232-243.
Crossref
Crossref
Felix Luessi. 2021. Translational Methods for Multiple Sclerosis Research. Translational Methods for Multiple Sclerosis Research
269
286
.
Kottil Rammohan, Patricia K. Coyle, Elke Sylvester, Andrew Galazka, Fernando Dangond, Megan Grosso & Thomas P. Leist. (2020) The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review. Drugs 80:18, pages 1901-1928.
Crossref
Crossref
Afreen Fatima & Amar Basu. (2019) Label Free Quantitation of Immunoglobulin G using the Stagnant Cap Hydrodynamic Retardation Effect Detector (SHRED). Label Free Quantitation of Immunoglobulin G using the Stagnant Cap Hydrodynamic Retardation Effect Detector (SHRED).
Matic Grom, Mirijam Kozorog, Simon Caserman, Andrej Pohar & Blaž Likozar. (2018) Protein A affinity chromatography of Chinese hamster ovary (CHO) cell culture broths containing biopharmaceutical monoclonal antibody (mAb): Experiments and mechanistic transport, binding and equilibrium modeling. Journal of Chromatography B 1083, pages 44-56.
Crossref
Crossref
Carlos Cuesta-Mateos, Ana Alcaraz-Serna, Beatriz Somovilla-Crespo & Cecilia Muñoz-Calleja. (2018) Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets. Frontiers in Immunology 8.
Crossref
Crossref
Matt Shirley. (2017) Daclizumab: A Review in Relapsing Multiple Sclerosis. Drugs 77:4, pages 447-458.
Crossref
Crossref
Miguel Angel Robles Sanchez & Bernadette Porter. (2015) The role of the MS clinical nurse specialist in the management of disease-modifying drugs. British Journal of Neuroscience Nursing 11:6, pages 272-278.
Crossref
Crossref
Joseph M. Cantor. (2014) CD98 is a potential target for ablating B cell clonal expansion and autoantibody in multiple sclerosis. Journal of Neuroimmunology 274:1-2, pages 230-233.
Crossref
Crossref
Lucienne Chatenoud. 2014. The Autoimmune Diseases. The Autoimmune Diseases
1221
1245
.
Giancarlo Comi, Mario Alberto Battaglia, Antonio Bertolotto, Massimo Del Sette, Angelo Ghezzi, Giovanni Malferrari, Marco Salvetti, Maria Pia Sormani, Luigi Tesio, Erwin Stolz & Gianluigi Mancardi. (2013) Italian multicentre observational study of the prevalence of CCSVI in multiple sclerosis (CoSMo study): rationale, design, and methodology. Neurological Sciences 34:8, pages 1297-1307.
Crossref
Crossref
Graziella Filippini, Cinzia Del Giovane, Laura Vacchi, Roberto D'Amico, Carlo Di Pietrantonj, Deirdre Beecher & Georgia Salanti. (2013) Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Fariha Zaheer & Joseph R. Berger. (2012) Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps. Therapeutic Advances in Drug Safety 3:5, pages 227-239.
Crossref
Crossref
Jonas V. Schaefer & Andreas Plückthun. (2012) Engineering Aggregation Resistance in IgG by Two Independent Mechanisms: Lessons from Comparison of Pichia pastoris and Mammalian Cell Expression. Journal of Molecular Biology 417:4, pages 309-335.
Crossref
Crossref
Sten Fredrikson & Jan HillertFelix LuessiFrauke Zipp. 2012. Emerging Oral Medications for Multiple Sclerosis. Emerging Oral Medications for Multiple Sclerosis
18
38
.
Brian S Sheridan & Leo Lefrançois. (2011) Regional and mucosal memory T cells. Nature Immunology 12:6, pages 485-491.
Crossref
Crossref
Gail Workman & E. Helene Sage. (2011) Identification of a sequence in the matricellular protein SPARC that interacts with the scavenger receptor stabilin-1. Journal of Cellular Biochemistry 112:4, pages 1003-1008.
Crossref
Crossref
Graziella Filippini, Cinzia Del Giovane, Laura Vacchi, Roberto D'Amico, Carlo Di Pietrantonj, Deirdre Beecher & Georgia Salanti. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.